PureTech Health plc (PTCHF)
| Market Cap | 411.10M |
| Revenue (ttm) | 468.00K |
| Net Income (ttm) | -82.47M |
| Shares Out | n/a |
| EPS (ttm) | -0.30 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 1,535 |
| Open | 1.670 |
| Previous Close | 1.670 |
| Day's Range | 1.670 - 1.670 |
| 52-Week Range | 1.670 - 3.000 |
| Beta | 0.99 |
| RSI | 11.92 |
| Earnings Date | Apr 25, 2025 |
About PureTech Health
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the ... [Read more]
Financial Performance
In 2023, PureTech Health's revenue was $3.33 million, a decrease of -78.68% compared to the previous year's $15.62 million. Losses were -$65.70 million, 30.5% more than in 2022.
Financial StatementsNews
Zentalis Pharmaceuticals and PureTech Health get Fast Track Designation from FDA for their cancer treatments
FDA grants Fast Track Designation to Zentalis Pharmaceuticals' azenosertib for ovarian cancer and PureTech Health's LYT-200 for leukemia treatment.
PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)
BOSTON--(BUSINESS WIRE)--PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML).
PureTech Appoints UBS as UK Corporate Broker
BOSTON--(BUSINESS WIRE)--PureTech Appoints UBS as UK Corporate Broker.
Why Edgewise Therapeutics Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket
Shares of Edgewise Therapeutics, Inc. (NASDAQ: EWTX) rose sharply in today's pre-market trading after the company reported topline results from Phase 2 CANYON trial of Sevasemten in individuals with ...
PureTech's Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the Primary and Key Secondary Endpoints in the ELEVATE IPF Phase 2b Trial
BOSTON--(BUSINESS WIRE)--PureTech's Deupirfenidone Slowed Lung Function Decline in People w/ IPF, Achieving the Primary & Key Secondary Endpoints in ELEVATE IPF Phase 2b Trial.
PureTech Founded Entity Seaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting 2024
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting 2024.
PureTech Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting
BOSTON--(BUSINESS WIRE)--PureTech Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting.
PureTech Founded Entity Seaport Therapeutics Adds Sandi Peterson to its Board of Directors
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Adds Sandi Peterson to its Board of Directors.
CITIGROUP INC Acquires New Stake in PureTech Health PLC
CITIGROUP INC Acquires New Stake in PureTech Health PLC
PureTech to Present at CHEST 2024 Annual Meeting
BOSTON--(BUSINESS WIRE)--PureTech to Present at CHEST 2024 Annual Meeting.
PureTech Health plc (PRTC) Q2 2024 Earnings Call Transcript
PureTech Health plc (NASDAQ:NASDAQ:PRTC) Q2 2024 Earnings Conference Call August 28, 2024 9:00 AM ETCompany ParticipantsAllison Mead Talbot - Head of...
PureTech Health plc – Half-Year Report
BOSTON--(BUSINESS WIRE)--PureTech Health plc – Half-Year Report.
PureTech Health: Notice of Half-Yearly Results
BOSTON--(BUSINESS WIRE)--PureTech Health: Notice of Half-Yearly Results.
PureTech Health: Results of the Tender Offer
BOSTON--(BUSINESS WIRE)--PureTech Health: Results of the Tender Offer.
PureTech Announces Change of Board Role
BOSTON--(BUSINESS WIRE)--Raju Kucherlapati, PhD, has been appointed Chair of the PureTech Board of Directors.
PureTech Founded Entity Seaport Therapeutics Appoints Seasoned Executives to Management Team
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Appoints Seasoned Executives to Management Team.
PureTech Health: Results of Annual General Meeting
BOSTON--(BUSINESS WIRE)--PureTech Health: Results of AGM.
PureTech Health: Result of General Meeting
BOSTON--(BUSINESS WIRE)--PureTech Health: Result of General Meeting.
PureTech Founded Entity Akili Interactive and Virtual Therapeutics Announce Entering Into Definitive Merger Agreement to Establish Leading Digital Health Company
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Akili Interactive and Virtual Therapeutics Enter Into Definitive Merger Agreement to Establish Leading Digital Health Company.
PureTech to Present at the Jefferies Global Healthcare Conference
BOSTON--(BUSINESS WIRE)--PureTech to Present at the Jefferies Global Healthcare Conference.
PureTech Founded Entity Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile Infection
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 Study of VE303.
PureTech Health: Launch of Proposed $100 Million Tender Offer at 250 Pence Per Ordinary Share
BOSTON--(BUSINESS WIRE)--PureTech Health: Launch of Proposed $100 million Tender Offer at 250 pence per Ordinary Share.
PureTech Founded Entity Seaport Therapeutics Presents Data from Multiple SPT-300 Trials at Society of Biological Psychiatry (SOBP) Annual Meeting
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Presents Data from Multiple SPT-300 Trials at Society of Biological Psychiatry (SOBP) Annual Meeting.
PureTech Founded Entity Seaport Therapeutics Adds Industry Veteran to Board of Directors and Makes Key Executive Appointments
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Adds Industry Veteran to Board of Directors and Makes Key Executive Appointments.
PureTech Health plc (PRTC) Q4 2023 Earnings Call Transcript
PureTech Health plc (NASDAQ:PRTC) Q4 2023 Earnings Conference Call April 25, 2024 9:00 AM ET Company Participants Allison Mead Talbot - Head, Communications Bharatt Chowrira - Chief Executive Officer...